Naïve exosomes can be engineered to load drugs into their lumen using two different technologies: passive drug loading and active drug loading. These “drugs” can include RNAs, proteins, and nucleic acids, as well as other payloads. Today, a growing number of companies are using engineered exosomes for therapeutic purposes and studies by these companies have confirmed that exosomes can effectively serve as carrier vehicles for several types of bioactive molecules. Several exosome therapeutics have also entered into clinical testing. [Read more…]
EV Biologics Generates Mesenchymal Stem Cell Lines
TAMPA, FL, February 21, 2023 – EV Biologics Corp (OTC PINK:YECO), announced that it has successfully generated several mesenchymal stem/stromal cell (MSC) lines for secretome production and further cell line development. The cell banks were isolated from rigorously screened human donor tissue using xeno-free, serum-free culture media for isolation and expansion, after obtaining informed consent (from donors) for research and development. Analysis of the cell lines confirmed their identity as MSCs according to established criteria. [Read more…]
New Super-Potent Topical Exosome Cosmetics Product, Distributed in UAE by Great Look Medical Supplies, to be Unveiled at Dubai Derma 2023 Conference March 1st- 3rd
ROCHESTER, NY and DUBAI, UAE, Feb. 17, 2023 – On March 1, Resiliélle Cosmetics, LLC and Regenerelle Biotherapeutics will unveil their new Resiliélle brand topical exosome cosmetics product manufactured by Regenerelle and exclusively distributed worldwide by Resiliélle. Resiliélle’s product will set a new standard for skin rejuvenation and lustrous hair. For optimal results, aesthetics professionals may use Resiliélle topically after microneedling or laser treatments. Resiliélle believes that the use of our topical exosome cosmetics will allow MedSpa, Dermatology and Plastic Surgery patients to use Resiliélle topical exosome cosmetics that have been developed to help patients to Leap Back In Time™ — At Any Age.™ [Read more…]
The Crowley Center for Regenerative & Biotherapeutics Names New Scientific Officer
Dr. Michael Heke, Ph.D. will drive integration of exosome-based topical cosmetics, regenerative biotherapeutics medical and scientific intelligence, and as well as aspects of patient safety as Managing Director-Scientific Officer.
Rochester, NY, February 8, 2023 — The Crowley Center™ for Regenerative & Biotherapeutics, LLC (aka AT Venture Center™, LLC) today announced that Dr. Heke has been appointed as Chief Scientific Officer of The Crowley Center, and its subsidiaries, Regenerelle™ Cellular & Exosome Biotherapeutics, Resiliélle™ Exosome Cosmetics, Sanatela® Regenerative Medical, Sanatela® AT Medical Solutions, Sanatela® Precision Cancer Diagnostics, Sanatela® Animal Biotechnologies, Sanatela® Biotechnologies, Sanatela® Matrix, Sanatela® Life Sciences and AT Venture Center for Global Techtrepreneurship™. Regenerelle’s and Sanatela’s IP technologies are both Patent Pending. [Read more…]
Venture Capital Flows into the Exosome Industry Led by Industry Stalwarts
Venture capital activity within the exosome industry has gained substantial momentum in recent years, as more as more investors pursue this promising cell-free therapeutic technology. While funding events slowed in the past year and a half due to the Covid pandemic, funding events from 2016 to 2021 were particularly robust—with companies like Evox Therapeutics, ILIAS Biologics, Codiak BioSciences, ExCoBio, Evox Therapeutics, ArunA Bio, and Capricor Therapeutics leading the charge. [Read more…]
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 27
- Next Page »